[{"id":"24a9df1f-6dbc-4a16-8c54-13431c420129","acronym":"EXCLAIM","url":"https://clinicaltrials.gov/study/NCT02716116","created_at":"2021-01-17T17:11:37.814Z","updated_at":"2024-07-02T16:35:32.901Z","phase":"Phase 1/2","brief_title":"A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02716116 - EXCLAIM","lead_sponsor":"Takeda","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R • HER-2 exon 23 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Exkivity (mobocertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 334","initiation":"Initiation: 06/16/2016","start_date":" 06/16/2016","primary_txt":" Primary completion: 03/28/2025","primary_completion_date":" 03/28/2025","study_txt":" Completion: 03/28/2025","study_completion_date":" 03/28/2025","last_update_posted":"2023-10-18"}]